MiNK Therapeutics, Inc. Logo

MiNK Therapeutics, Inc.

Develops allogeneic iNKT cell therapies for cancer and immune-mediated diseases.

INKT | US

Overview

Corporate Details

ISIN(s):
US6036931029
LEI:
Country:
United States of America
Address:
149 FIFTH AVENUE, 10010 NEW YORK

Description

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MiNK Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MiNK Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MiNK Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alzinova AB Logo
Clinical-stage biopharma developing immunotherapies for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops and commercializes therapeutics to improve cardiovascular health.
United States of America
AMRN
AMGEN INC Logo
A biotechnology company developing human therapeutics for serious illnesses.
United States of America
AMGN
Industrial biotechnology company specializing in specialty enzymes and proteins.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Biotechnology company developing therapies for rare genetic and devastating diseases.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Specialty manufacturer of high-purity chiral amino acids and their derivatives.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops, manufactures, and distributes generic and specialty pharmaceuticals.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops, manufactures, and markets technically challenging medications.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Develops therapies for neurodegenerative diseases and other unmet medical needs.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Biopharmaceutical firm developing boron-based drugs for infectious diseases.
United States of America
ANTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.